Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/13677
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tantitamit T. | |
dc.contributor.author | Huang K.-G. | |
dc.contributor.author | Manopunya M. | |
dc.contributor.author | Yen C.-F. | |
dc.date.accessioned | 2021-04-05T03:25:35Z | - |
dc.date.available | 2021-04-05T03:25:35Z | - |
dc.date.issued | 2018 | |
dc.identifier.issn | 22133070 | |
dc.identifier.other | 2-s2.0-85046877592 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/13677 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046877592&doi=10.4103%2fGMIT.GMIT-10-18&partnerID=40&md5=e5fa66474d0b28e75483a2e6337dabeb | |
dc.description.abstract | Uterine leiomyosarcoma (uLMS) is a rare and aggressive cancer, usually diagnosed incidentally at the time of myomectomy or hysterectomy. There have been concerns for several years about the fact that the inadvertent disruption of occult uLMS may have a negative impact on patient outcome. This study reviews the outcome and management of patients with a diagnosis of uLMS after surgery for presumed benign disease. We conducted a literature search in which 47 published English-language articles were obtained for evaluation. A total of 23 studies with outcomes data were included. It is evidenced that patients who underwent surgery with tumor disruption resulted in poorer outcomes compared with en bloc tumor, especially by power morcellation. The power morcellation was associated with an increased risk of recurrence, shorten time to recurrence, and upstage after re-exploration. Early re-exploration and surgical staging are appreciated for better prognosis and may alter postoperative treatment. We also updated on the incidence and preoperative evaluation to assess the risk of patient and give an effective counseling. © 2018 Gynecology and Minimally Invasive Therapy | Published by Wolters Kluwer - Medknow. | |
dc.subject | CA 125 antigen | |
dc.subject | fluorodeoxyglucose | |
dc.subject | abdominal hysterectomy | |
dc.subject | antibody blood level | |
dc.subject | cancer prognosis | |
dc.subject | cancer risk | |
dc.subject | cancer staging | |
dc.subject | cancer survival | |
dc.subject | clinical effectiveness | |
dc.subject | color Doppler flowmetry | |
dc.subject | conservative treatment | |
dc.subject | disease marker | |
dc.subject | echography | |
dc.subject | female | |
dc.subject | female fertility | |
dc.subject | human | |
dc.subject | incidence | |
dc.subject | leiomyosarcoma | |
dc.subject | myomectomy | |
dc.subject | nuclear magnetic resonance imaging | |
dc.subject | outcome assessment | |
dc.subject | peak systolic velocity | |
dc.subject | positron emission tomography | |
dc.subject | preoperative evaluation | |
dc.subject | priority journal | |
dc.subject | recurrence risk | |
dc.subject | reproductive success | |
dc.subject | Review | |
dc.subject | risk factor | |
dc.subject | salpingooophorectomy | |
dc.subject | survival rate | |
dc.subject | treatment outcome | |
dc.subject | treatment response | |
dc.subject | tumor volume | |
dc.subject | ultrasound | |
dc.subject | uterine leiomyosarcoma | |
dc.subject | uterus disease | |
dc.subject | uterus sarcoma | |
dc.subject | uterus weight | |
dc.title | Outcome and management of uterine leiomyosarcoma treated following surgery for presumed benign disease: Review of literature | |
dc.type | Review | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Gynecology and Minimally Invasive Therapy. Vol 7, No.2 (2018), p.47-55 | |
dc.identifier.doi | 10.4103/GMIT.GMIT-10-18 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.